Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001628280-25-003184
Filing Date
2025-01-30
Accepted
2025-01-30 16:39:07
Documents
1
Period of Report
2024-03-25

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wk-form4a_1738273141.html 4/A  
1 FORM 4/A wk-form4a_1738273141.xml 4/A 3583
  Complete submission text file 0001628280-25-003184.txt   5012
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2525 WEST END AVE., SUITE 950 NASHVILLE TN 37203
Business Address
Jones James (Reporting) CIK: 0001490829 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-33637 | Film No.: 25574323